Department of Pathology, Affiliated Hospital 2 of Nantong University, Nantong, Jiangsu, China.
Department of Radiation Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Medicine (Baltimore). 2023 Sep 29;102(39):e34559. doi: 10.1097/MD.0000000000034559.
Coronavirus disease 2019 (COVID-19) is still rampant and uncontrolled across the globe. China's strict epidemic prevention measures have had an impact on the treatment in patients with non-small cell lung cancer (NSCLC). The aim of this study is to explore the impact of the COVID-19 outbreak on the uninfected NSCLC patients. The chemotherapeutic efficacy and survival of 89 uninfected advanced NSCLC patients were retrospectively analyzed. The endpoints were overall survival (OS), progression-free survival (PFS), and response rate. Forty and forty-nine patients with advanced NSCLC received chemotherapy during the COVID-19 outbreak and nonoutbreak periods, respectively. Mean delay time was 12.8 months for COVID-19 outbreak stage versus 5.68 months for nonoutbreak stage (P = .003). There was no significant difference in the rates of chemotherapy delay and discontinuation between the 2 groups (P = .055 and .239). Significant difference was not detected in median OS (15.8 months) for COVID-19 outbreak stage versus 16.0 months for nonoutbreak stage (adjusted hazard ratio, 1.058; 95% confidence interval, 0.593-1.888; P = .849); Median PFS was 7.9 months for COVID-19 outbreak stage versus 10.3 months for nonoutbreak stage (adjusted hazard ratio, 0.878; 95% confidence interval 0.513-1.503; P = .634). There was also no statistical difference in the disease control rate between the 2 groups (P = .137). The earliest COVID-19 outbreak had no significant impact on the PFS and OS in uninfected advanced NSCLC patients receiving chemotherapy. However, the mean delay time of receiving chemotherapy was prolonged during the COVID-19 outbreak.
新型冠状病毒病（COVID-19）在全球范围内仍在肆虐且无法控制。中国严格的疫情防控措施对非小细胞肺癌（NSCLC）患者的治疗产生了影响。本研究旨在探讨 COVID-19 大流行对未感染 NSCLC 患者的影响。回顾性分析了 89 例未感染的晚期 NSCLC 患者的化疗疗效和生存情况。终点是总生存期（OS）、无进展生存期（PFS）和反应率。40 例和 49 例晚期 NSCLC 患者分别在 COVID-19 大流行期间和非大流行期间接受化疗。COVID-19 大流行阶段的平均延迟时间为 12.8 个月，非大流行阶段为 5.68 个月（P=.003）。两组化疗延迟和停药率无显著差异（P=.055 和.239）。COVID-19 大流行阶段的中位 OS 为 15.8 个月，而非大流行阶段为 16.0 个月，差异无统计学意义（调整后的危险比为 1.058；95%置信区间为 0.593-1.888；P=.849）；COVID-19 大流行阶段的中位 PFS 为 7.9 个月，而非大流行阶段为 10.3 个月，差异无统计学意义（调整后的危险比为 0.878；95%置信区间 0.513-1.503；P=.634）。两组疾病控制率也无统计学差异（P=.137）。COVID-19 大流行的最早阶段对接受化疗的未感染晚期 NSCLC 患者的 PFS 和 OS 没有显著影响。然而，在 COVID-19 大流行期间，接受化疗的平均延迟时间延长了。
